Conversation With: Galderma USA President Francois Fournier

In September, Fort Worth-based pharmaceutical company Galderma was granted Food and Drug Administration approval for Mirvaso, the only topical drug approved to treat [the facial redness of] rosacea. The drug is expected to generate as much as $100 million in revenue for the company, which also produces Cetaphil, a popular over-the-counter skin care line. We sat down with Galderma USA president Francois Fournier to discuss the product, and Galderma’s future. In broad terms, what does Galderma do? It’s a very unique company because we specialize only in dermatology. It’s only about the patients with skin conditions. The inception of the company… Full Story